AI Drug Discovery Unicorn Emerges from Tech Giant
In a significant move within the tech-biotech crossover space, the artificial intelligence-driven drug discovery division of a leading technology company has completed its spin-off, emerging as an independent entity. The newly formed company has achieved a valuation of approximately $1 billion, reflecting strong investor confidence in AI-powered pharmaceutical research.
$200 Million Series A Funding and Elite Scientific Guidance
The venture has secured close to $200 million in its initial funding round and will establish its operational headquarters in Shanghai. This strategic move provides substantial capital for growth and leverages Shanghai's thriving biotech ecosystem.
To ensure scientific rigor, the company has convened a distinguished Scientific Advisory Board (SAB). The board features preeminent figures such as Dr. Yongjun Liu, former President of Innovent Biologics, and Dr. Ji Ma, former Chief Scientist at Amgen. Their expertise spans the entire drug development continuum, from target validation to clinical development, offering critical guidance for the company's pipeline.
Proven Tech Stack and Promising Pipeline
The core team originates from an AI drug discovery unit established in 2021, now led by Kai Liu, former Managing Director at Volcano Capital. A lean team of around 50 researchers operates across Shanghai, Singapore, and San Jose, USA, enabling global collaboration.
The team boasts a robust technological foundation. In 2025, they launched molecular structure prediction models, followed by iterative upgrades in 2026. They have also developed a proprietary tool for designing protein binders. To validate its approach, the team built the Anew Labs platform for AI-driven drug discovery.
Tangible progress is already visible. At a major immunology conference in April 2026, the team presented a novel small-molecule program targeting the IL-17 pathway. This project reportedly represents a world-first in using a single small molecule to simultaneously block three distinct dimers (AA/AF/FF) within the IL-17 family, demonstrating the platform's unique capabilities.
A New Chapter of Autonomy and Agility
Industry observers note that operating as a standalone company grants greater autonomy, flexibility in decision-making, and agility in talent acquisition. This structure allows it to adhere more closely to the long-term, capital-intensive rhythms of biotech R&D. Post-spin-off, the new company will continue to receive underlying computing power support from its former parent's cloud platform.
The final list of Series A investors is still being finalized. It is understood that several existing shareholders of the parent company and leading China-focused dollar funds are in advanced discussions, indicating significant market interest.